Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Breakthrough CMG901 Drug Introduced for Advanced Gastric Cancer

Connoya introduced CMG901, novel drug for the treatment of Claudin 18.2-positive advanced gastric cancer. This new drug is indicated after first-line or treatment failure or intolerance.

CMG901 previously granted orphan drug designation and fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory gastric cancer and gastroesophageal junction adenocarcinoma. Hence, CMG901 serves as the better treatment of Claudin 18.2-positive advanced gastric cancer.

Gastric cancer is a malignant tumor of epithelial origin originating from stomach. Globally, more than 1 million new gastric cancer cases arise every year causing nearly 769,000 deaths.

During first diagnosis, due to the atypical early symptoms of gastric cancer, 80% to 90% of gastric cancer patients are in the advanced stage, losing the chance of radical surgery.

Since gastric cancer is highly heterogeneous, the targeted therapy drugs are scarce. Currently, there are no targeted drugs approved for first-line treatment of HER2 in market.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024